Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
21.73
+0.41 (1.92%)
At close: May 22, 2026, 4:00 PM EDT
21.71
-0.02 (-0.09%)
After-hours: May 22, 2026, 7:59 PM EDT
Elanco Animal Health Revenue
Elanco Animal Health had revenue of $1.37B in the quarter ending March 31, 2026, with 14.92% growth. This brings the company's revenue in the last twelve months to $4.89B, up 10.53% year-over-year. In the year 2025, Elanco Animal Health had annual revenue of $4.72B with 6.22% growth.
Revenue (ttm)
$4.89B
Revenue Growth
+10.53%
P/S Ratio
2.22
Revenue / Employee
$494,242
Employees
9,900
Market Cap
10.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.72B | 276.00M | 6.22% |
| Dec 31, 2024 | 4.44B | 22.00M | 0.50% |
| Dec 31, 2023 | 4.42B | 6.00M | 0.14% |
| Dec 31, 2022 | 4.41B | -353.00M | -7.41% |
| Dec 31, 2021 | 4.76B | 1.49B | 45.64% |
| Dec 31, 2020 | 3.27B | 200.00M | 6.51% |
| Dec 31, 2019 | 3.07B | 4.20M | 0.14% |
| Dec 31, 2018 | 3.07B | 177.80M | 6.15% |
| Dec 31, 2017 | 2.89B | -24.50M | -0.84% |
| Dec 31, 2016 | 2.91B | 4.40M | 0.15% |
| Dec 31, 2015 | 2.91B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viatris | 14.56B |
| Dr. Reddy's Laboratories | 3.58B |
| United Therapeutics | 3.17B |
| Neurocrine Biosciences | 3.10B |
| Amneal Pharmaceuticals | 3.05B |
| Hims & Hers Health | 2.37B |
| Alkermes | 1.56B |
| Lantheus Holdings | 1.55B |
ELAN News
- 4 days ago - Elanco Animal Health Transcript: AGM 2026 - Transcripts
- 7 days ago - Elanco launches Befrena for canine allergic itch - TheFly
- 7 days ago - Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market - PRNewsWire
- 10 days ago - Elanco price target lowered to $23 from $24 at Morgan Stanley - TheFly
- 11 days ago - Elanco to Participate in Upcoming Investor Conferences - PRNewsWire
- 15 days ago - Elanco Animal Health Q1 Earnings Call Highlights - MarketBeat
- 18 days ago - Elanco price target raised to $30 from $28 at JPMorgan - TheFly
- 18 days ago - Elanco price target raised to $31 from $30 at Citi - TheFly